AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

NCT01030328 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of patient population

Conditions

Coronary Atherosclerosis

Interventions

DRUG: Placebo
DRUG: TriLipix

Sponsor

Piedmont Healthcare